|
Nov 29
|
Avidity (RNA) Expands Collaboration With BMY, Shares Rise
|
|
Nov 29
|
CAR T-Cell Therapies Under FDA Watch on Reports of Malignancies
|
|
Nov 28
|
FDA Looking Into All Approved CAR T Therapies on Risk of Cancer in White Blood Cells
|
|
Nov 28
|
Avidity Stock Soars on Collaboration Deal With Bristol Myers
|
|
Nov 28
|
Bristol Myers pours $100M into RNA drugs for cardiovascular diseases
|
|
Nov 28
|
Avidity Biosciences Announces Expansion of Cardiovascular Collaboration with Bristol Myers Squibb for up to Five Targets Utilizing Avidity's Proprietary AOC™ Platform Technology
|
|
Nov 26
|
3 Resilient Stocks with Massive Potential to Boost Your Wealth
|
|
Nov 26
|
15 Best Drug Stocks To Invest In
|
|
Nov 26
|
Bristol-Myers Squibb Company (NYSE:BMY) Delivered A Better ROE Than Its Industry
|
|
Nov 24
|
Don't Wait for a Market Crash: These 2 Top Stocks Are on Sale
|
|
Nov 14
|
Bristol Myers Squibb Proved in Q3 Why Its Diverse Portfolio Makes It a Solid Investment
|
|
Nov 14
|
12 Best Buy-the-Dip Stocks To Buy Now
|
|
Nov 14
|
Bristol-Myers Squibb Company's (NYSE:BMY) recent 4.1% pullback adds to one-year year losses, institutional owners may take drastic measures
|
|
Nov 13
|
Developing new medicines for everyone, everywhere, equally
|
|
Nov 13
|
Anthos blood thinner bests Xarelto on safety in mid-stage study
|
|
Nov 11
|
Merck and Bristol Myers Squibb Will Face Off in This 1 Market -- but Who Will Win?
|
|
Nov 10
|
Bristol-Myers Squibb (NYSE:BMY) shareholders have endured a 34% loss from investing in the stock a year ago
|
|
Nov 9
|
Bristol Myers Squibb to Participate in the 2023 Jefferies London Healthcare Conference
|
|
Nov 9
|
U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb’s Application for Breyanzi (lisocabtagene maraleucel) for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
|
|
Nov 8
|
Pharma ETFs in Focus Post Q3 Earnings
|